14101-91-8

Basic information

• Product Name: (Z)-heptadec-9-enoic acid methyl ester
• Synonyms: (Z)-heptadec-9-enoic acid methyl ester
• CAS NO: 14101-91-8
• Molecular Weight: 282.467
• Mol File: 14101-91-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (Z)-heptadec-9-enoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-heptadec-9-enoic acid methyl ester(14101-91-8)
• EPA Substance Registry System: (Z)-heptadec-9-enoic acid methyl ester(14101-91-8)

Safety Data

• Hazardous Substances Data: 14101-91-8(Hazardous Substances Data)

Usage

Description

(Z)-heptadec-9-enoic acid methyl ester is a chemical compound that belongs to the class of organic compounds known as long-chain fatty acids and derivatives. It is an ester derivative of (Z)-heptadec-9-enoic acid, which is a long-chain unsaturated fatty acid. (Z)-heptadec-9-enoic acid methyl ester is commonly found in various natural sources, including plants and animals.

Uses

Used in the Food Industry:
(Z)-heptadec-9-enoic acid methyl ester is used as an aroma compound to enhance the flavor and aroma of various food products. Its natural occurrence and pleasant scent make it a desirable additive in the industry.
Used in the Pharmaceutical Industry:
(Z)-heptadec-9-enoic acid methyl ester is used as an aroma compound in the pharmaceutical industry, where it can contribute to the overall sensory experience of medications, making them more palatable for patients.
Used as a Synthetic Intermediate:
(Z)-heptadec-9-enoic acid methyl ester is used as a synthetic intermediate in the production of various chemical products, leveraging its chemical properties to create a range of different compounds.
Used in Medical Research and Development:
(Z)-heptadec-9-enoic acid methyl ester has demonstrated potential biological activities, including antimicrobial and anti-inflammatory properties. As a result, it is a subject of interest in medical research and development, with potential applications in the creation of new treatments and therapies.

Upstream product

• 99669-96-2 1-chloro-7-iodo-heptane 
• 51526-03-5 1,ω-diiodoheptane 
• 3452-09-3 1-nonyne 
• 17696-11-6 8-bromooctanoic acid 
• 26825-92-3 methyl 8-bromooctanoate 
• 50816-19-8 8-bromooctanol 
• 25601-39-2 methyl heptadec-9-ynoate 
• 50816-20-1 2-(8-bromooctyloxy)tetrahydropyran 
• 67-56-1 methanol 
• 506-12-7 heptadecanoic acid 
• 10269-71-3 9-heptadecynoic acid 
• 3330-35-6 8-heptadecyne iodide 
• 1981-50-6 (9Z)-heptadec-9-enoic acid 

Downstream Products

• 1981-50-6 (9Z)-heptadec-9-enoic acid 
• 124-13-0 Octanal 
• 1931-63-1 methyl ester of azelaic acid aldehyde 
• 143-28-2 oleoyl alcohol 
• 506-42-3 (E)-9-octadecen-1-ol 

Relevant articles and documents

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.

Fatty acid desaturation and elongation reactions of trichoderma sp. 1-OH-2-3

The fatty acid desaturation and elongation reactions catalyzed by Trichoderma sp. 1-OH-2-3 were investigated. This strain converted palmitic acid (16:0) mainly to stearic acid (18:0), and further to oleic acid (c9-18:1), linoleic acid (c9,c12-18:2), and α-linolenic acid (c9,c12,c15-18:3) through elongation, and Δ9, Δ12, and Δ15 desaturation reactions, respectively. Palmitoleic acid (c9-16:1) and cis-9,cis-12- hexadecadienoic acid were also produced from 16:0 by the strain. This strain converted n-tridecanoic acid (13:0) to cis-9-heptadecenoic acid and further to cis-9,cis-12-heptadecadienoic acid through elongation, and Δ9 and Δ12 desaturation reactions, respectively. trans-Vaccenic acid (t11-18:1) and trans-12-octadecenoic acid (t12-18:1) were desaturated by the strain through Δ9 desaturation. The products derived from t11-18:1 were identified as the conjugated linoleic acids (CLAs) of cis-9,trans-11-octadecadienoic acid and trans-9,trans-11-octadecadienoic acid. The product derived from t12-18:1 was identified as cis-9,trans-12-octadecadienoic acid. cis-6,cis-9-Octadecadienoic acid was desaturated to cis-6,cis-9,cis-12-octadecatrienoic acid by this strain through Δ12 desaturation. The broad substrate specificity of the elongation, and Δ9 and Δ12 desaturation reactions of the strain is useful for fatty acid biotransformation.